Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results at Week 12 from the phase 3 GRAVITI study

被引：0
|
作者：
D'Haens, G. [1 ]
Hisamatsu, T. [2 ]
Steinwurz, F. [3 ]
Hart, A. [4 ]
Liu, W. [5 ]
Olurinde, M. [6 ]
Ngqawa, P. [6 ]
Yang, Z. [6 ]
Merrall, E. [7 ]
Terry, N. A. [6 ]
Sands, B. E. [8 ]
Panaccione, R. [9 ]
机构：
[1] Amsterdam Univ Med Ctr, Gastroenterol, Amsterdam, Netherlands
[2] Kyorin Univ, Gastroenterol, Tokyo, Japan
[3] Hosp Israelita Albert Einstein, Gastroenterol, Sao Paulo, Brazil
[4] London North West Univ Healthcare NHS Trust, Gastroenterol, London, England
[5] Nanjing Med Univ, Affiliated Hosp 3, Peoples Hosp Changzhou 2, Gastroenterol, Changzhou, Peoples R China
[6] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[7] Janssen Vaccines & Prevent BV, Immunol, Leiden, Netherlands
[8] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[9] Univ Calgary, Gastroenterol, Calgary, AB, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1017
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0843
引用
收藏
页码：I1608 / I1609
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
    Panaccione, Remo
    Hart, Ailsa
    Steinwurz, Flavio
    Danese, Silvio
    Hisamatsu, Tadakazu
    Cao, Qian
    Olurinde, Mobolaji
    Vetter, Marion
    Yang, Zijiang
    Wang, Yuhua
    Johanns, Jewel
    Terry, Natalie A.
    Sands, Bruce E.
    D'Haens, Geert R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S740 - S741
  • [2] Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results through Week 48 from the phase 3 GRAVITI study
    Hart, A.
    Panaccione, R.
    Steinwurz, F.
    Danese, S.
    Hisamatsu, T.
    Cao, Q.
    Olurinde, M.
    Vetter, M. L.
    Yang, Z.
    Wang, Y.
    Johanns, J.
    Terry, N. A.
    Sands, B. E.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i66 - i67
  • [3] Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn's disease: Results from the phase 3 GRAVITI study
    Hart, A.
    Hisamatsu, T.
    Steinwurz, F.
    D'Haens, G.
    Liu, W.
    Olurinde, M.
    Ngqawa, P.
    Yang, Z.
    Merrall, E.
    Terry, N. A.
    Panaccione, R.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1312 - i1314
  • [4] Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn's disease: Phase 3 GRAVITI study results through week 48
    Hart, A.
    Panaccione, R.
    Steinwurz, F.
    Cao, Q.
    Hisamatsu, T.
    Nancey, S.
    Olurinde, M.
    Yang, Z.
    Merrall, E.
    Terry, N. A.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1662 - i1663
  • [5] Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn's disease: Subgroup analysis of the Phase 3 GRAVITI study
    Liu, W.
    Guo, H.
    Kim, T. O.
    Takeuchi, K.
    Hisamatsu, T.
    Fable, J.
    Olurinde, M.
    Wahking, B.
    Zhuo, J.
    Cao, Q.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1899 - I1901
  • [6] Efficacy of Guselkumab in Patients With Moderately to Severely Active Crohn's Disease Not in Clinical Response at Week 12: Results From the GALAXI 1 Study
    Panaccione, Remo
    Afzali, Anita
    D'Haens, Geert R.
    Salese, Leonardo
    Terry, Natalie A.
    Sahoo, Aparna
    Frustaci, Mary Ellen
    Yang, Zijiang
    Zittan, Eran
    Danese, Silvio
    Hisamatsu, Tadakazu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S626 - S626
  • [7] THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
    Sands, Bruce E.
    Danese, Silvio
    Andrews, Jane M.
    Weisel, Kathleen
    Chan, Daphne
    Johanns, Jewel
    Frustaci, Mary Ellen S.
    Yang, Zijian
    Cunningham, Melissa
    Ghanem, Louis
    Panaccione, Remo
    Afzali, Anita
    Sandborn, William J.
    GASTROENTEROLOGY, 2021, 160 (06) : S350 - S351
  • [8] Effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 study
    Sands, B.
    Danese, S.
    Andrews, J.
    Weisel, K.
    Chan, D.
    Johanns, J.
    Frustaci, M. E.
    Yang, Z.
    Cunningham, M.
    Ghanem, L.
    Panaccione, R.
    Afzali, A.
    Sandborn, W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 108 - 109
  • [9] THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON ENDOSCOPIC OUTCOME MEASURES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
    D'Haens, Geert
    Rubin, David T.
    Panes, Julian
    Gonzalez, Susana
    Chan, Daphne
    Johanns, Jewel
    Frustaci, Mary Ellen S.
    Yang, Zijiang
    Adedokun, Omoniyi J.
    Cunningham, Melissa
    Ghanem, Louis
    Reinisch, Walter
    Hisamatsu, Tadakazu
    Feagan, Brian G.
    GASTROENTEROLOGY, 2021, 160 (06) : S91 - S91
  • [10] Effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 study
    Leong, R. W-L
    D'Haens, G.
    Rubin, D. T.
    Panes, J.
    Gonzalez, S.
    Chan, D.
    Johanns, J.
    Frustaci, M. E.
    Yang, Z.
    Adedokun, O. J.
    Cunningham, M.
    Ghanem, L.
    Reinisch, W.
    Hisamatsu, T.
    Feagan, B. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 169 - 170
12345